Psychopharmacology

, Volume 216, Issue 3, pp 367–378

Increased cocaine self-administration in M4 muscarinic acetylcholine receptor knockout mice

  • Lene S. Schmidt
  • Morgane Thomsen
  • Pia Weikop
  • Ditte Dencker
  • Jürgen Wess
  • David P. D. Woldbye
  • Gitta Wortwein
  • Anders Fink-Jensen
Original Investigation

Abstract

Rationale

The reinforcing effects of cocaine are mediated by the mesolimbic dopamine system. Behavioral and neurochemical studies have shown that the cholinergic muscarinic M4 receptor subtype plays an important role in regulation of dopaminergic neurotransmission.

Objectives

Here we investigated for the first time the involvement of M4 receptors in the reinforcing effects of cocaine using chronic intravenous cocaine self-administration in extensively backcrossed M4 receptor knockout (M4−/−) mice.

Methods

We evaluated acquisition of cocaine self-administration in experimentally naïve mice. Both cocaine self-administration and food-maintained operant behavior were evaluated under fixed ratio 1 (FR 1) and progressive ratio (PR) schedules of reinforcement. In addition, cocaine-induced dopamine release and cocaine-induced hyperactivity were evaluated.

Results

M4−/− mice earned significantly more cocaine reinforcers and reached higher breaking points than their wild-type littermates (M4+/+) at intermediate doses of cocaine under both FR 1 and PR schedules of reinforcement. Under the PR schedule, M4−/− mice exhibited significantly higher response rates at the lowest liquid food concentration. In accordance with these results, cocaine-induced dopamine efflux in the nucleus accumbens and hyperlocomotion were increased in M4−/− mice compared to M4+/+ mice.

Conclusions

Our data suggest that M4 receptors play an important role in regulation of the reward circuitry and may serve as a new target in the medical treatment of drug addiction.

Keywords

Acetylcholine Muscarinic M4 Knockout Self-administration Cocaine 

Supplementary material

213_2011_2225_MOESM1_ESM.doc (48 kb)
Supplemental Table 1Behavioral phenotype assessment, primary screen (SHIRPA). Body weight, body length, and locomotor activity (bb, beam breaks) are group means ± SEM. Other data are group medians with range in parenthesis. Groups sizes, n = 1921. There was no significant effect of genotype in any of the measures. (DOC 47 kb)

References

  1. Brady AE, Jones CK, Bridges TM, Kennedy JP, Thompson AD, Heiman JU, Breininger ML, Gentry PR, Yin H, Jadhav SB, Shirey JK, Conn PJ, Lindsley CW (2008) Centrally active allosteric potentiators of the M4 muscarinic acetylcholine receptor reverse amphetamine-induced hyperlocomotor activity in rats. J Pharmacol Exp Ther 327(3):941–953PubMedCrossRefGoogle Scholar
  2. Caine SB, Negus SS, Mello NK (1999) Method for training operant responding and evaluating cocaine self-administration behavior in mutant mice. Psychopharmacol (Berl) 147:22–24CrossRefGoogle Scholar
  3. Caine SB, Negus SS, Mello NK, Patel S, Bristow L, Kulagowski J, Vallone D, Saiardi A, Borrelli E (2002) Role of dopamine D2-like receptors in cocaine self-administration: studies with D2 receptor mutant mice and novel D2 receptor antagonists. J Neurosci 22(7):2977–2988PubMedGoogle Scholar
  4. Caine SB, Thomsen M, Gabriel KI, Berkowitz JS, Gold LH, Koob GF, Tonegawa S, Zhang J, Xu M (2007) Lack of self-administration of cocaine in dopamine D1 receptor knock-out mice. J Neurosci 27(48):13140–13150PubMedCrossRefGoogle Scholar
  5. Camps M, Kelly PH, Palacios JM (1990) Autoradiographic localization of dopamine D1 and D2 receptors in the brain of several mammalian species. J Neuronal Transm Gen Sect 80:105–127CrossRefGoogle Scholar
  6. Chan WY, McKinzie DL, Bose S, Mitchell SN, Witkin JM, Thompson RC, Christopoulos LS, Birdsall NJM, Bymaster FP, Felder CC (2008) Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia. PNAS 105:10978–10983PubMedCrossRefGoogle Scholar
  7. Chen SR, Wess J, Pan HL (2005) Functional activity of the M2 and M4 receptor subtypes in the spinal cord studied with muscarinic acetylcholine receptor knockout mice. J Pharmacol Exp Ther 313(2):765–770Google Scholar
  8. Chiamulera C, Epping-Jordan MP, Zocchi A, Marcon C, Cottiny C, Tacconi S, Corsi M, Orzi F, Conquet F (2001) Reinforcing and locomotor stimulant effects of cocaine are absent in mGluR5 null mutant mice. Nat Neurosci 4(9):873–874PubMedCrossRefGoogle Scholar
  9. Di Chiara G, Morelli M, Consolo S (1994) Modulatory functions of neurotransmitters in the striatum: ACh/dopamine/NMDA interactions. Trends Neurosci 17:228–233PubMedCrossRefGoogle Scholar
  10. Fink-Jensen A, Fedorova I, Wörtwein G, Woldbye DP, Rasmussen T, Thomsen M, Bolwig TG, Knitowski KM, McKinzie DL, Yamada M, Wess J, Basile A (2003) Role for M5 muscarinic acetylcholine receptors in cocaine addiction. J Neurosci Res 74(1):91–96PubMedCrossRefGoogle Scholar
  11. Franklin KJB, Paxinos G (1997) The mouse brain in stereotaxic coordinates. Academic, New YorkGoogle Scholar
  12. Gerlai R (1996) Gene-targeting studies of mammalian behavior: is it the mutation or the background genotype? Trends Neurosci 19:177–181PubMedCrossRefGoogle Scholar
  13. Gomeza J, Zhang L, Kostenis E, Felder C, Bymaster F, Brodkin J, Shannon H, Xia B, Deng CX, Wess J (1999) Enhancement of D1 dopamine receptor-mediated locomotor stimulation in M4 muscarinic acetylcholine receptor knockout mice. Proc Natl Acad Sci USA 96:10483–10488PubMedCrossRefGoogle Scholar
  14. Hulme EC, Birdsall NJM, Buckley N (1990) Muscarinic receptor subtypes. Annu Rev Pharmacol Toxicol 30:633–673PubMedCrossRefGoogle Scholar
  15. Ince E, Ciliax BJ, Levey AI (1997) Differential expression of D1 and D2 dopamine and m4 muscarinic acetylcholine receptor proteins in identified striatonigral neurons. Synapse 27:357–366PubMedCrossRefGoogle Scholar
  16. Irwin S (1968) Comprehensive observational assessment: Ia. A systematic, quantitative procedure for assessing the behavioral and physiologic state of the mouse. Psychopharmacologia 13:222–257PubMedCrossRefGoogle Scholar
  17. Jeon J, Dencker D, Wörtwein G, Woldbye DPD, Cui Y, Davis AA, Levey AI, Schütz G, Sager TN, Mørk A, Li C, Deng C, Fink-Jensen A, Wess J (2010) A subpopulation of neuronal M4 muscarinic acetylcholine receptors plays a critical role in modulation dopamine-dependent behaviors. J Neurosci 30(6):2396–2405PubMedCrossRefGoogle Scholar
  18. Koob GF (1992) Drugs of abuse: anatomy, pharmacology and function of reward pathways. Trends Pharmacol Sci 13:177–184PubMedCrossRefGoogle Scholar
  19. Koob GF, Sanna PP, Bloom FE (1998) Neuroscience of addiction. Neuron 21:467–476PubMedCrossRefGoogle Scholar
  20. Lalonde R, Dumont M, Staufenbiel M, Strazielle C (2005) Neurobehavioral characterization of APP23 transgenic mice with the SHIRPA primary screen. Behav Brain Res 157:91–98PubMedCrossRefGoogle Scholar
  21. Levey AI (1993) Immunological localization of m1–m5 muscarinic acetylcholine receptors in peripheral tissues and brain. Life Sci 52:441–448PubMedCrossRefGoogle Scholar
  22. Olianas MC, Adem A, Karlsson E, Onali P (1996) Rat striatal muscarinic receptors coupled to the inhibition of adenylyl cyclase activity: potent block by the selective m4 ligand muscarinic toxin 3 (MT3). Br J Pharmacol 118:283–288PubMedGoogle Scholar
  23. Piaza PV, Deroche-Gamonent V, Rouge-Pont F, Le Moal M (2000) Vertical shifts in self-administration dose–response functions predict a drug-vulnerable phenotype predisposed to addiction. J Neurosci 20(11):4226–4232Google Scholar
  24. Rocha BA, Ator R, Emmett-Oglesby MW, Hen R (1997) Intravenous cocaine self-administration in mice lacking 5-HT1B receptors. Pharmacol Biochem Behav 57(3):407–412Google Scholar
  25. Rocha BA, Fumagalli F, Gainetdinov RR, Jones SR, Ator R, Giros B, Miller GW, Caron MG (1998a) Cocaine self-administration in dopamine-transporter knockout mice. Nat Neurosci 2:132–137, Erratum in: Nat Neurosci 1(4):330Google Scholar
  26. Rocha BA, Scearce-Levie K, Lucas JJ, Hiroi N, Castanon N, Crabbe JC, Nestler EJ, Hen R (1998b) Increased vulnerability to cocaine in mice lacking the serotonin-1B receptor. Nature 939(6681):175–178Google Scholar
  27. Rogers DC, Fisher EM, Brown SD, Peters J, Hunter AJ, Martin JE (1997) Behavioral and functional analysis of mouse phenotype: SHIRPA, a proposed protocol for comprehensive phenotype assessment. Mamm Genome 8:711–713PubMedCrossRefGoogle Scholar
  28. Rogers DC, Jones DN, Nelson PR, Jones CM, Quilter CA, Robinson TL, Hagan JJ (1999) Use of SHIRPA and discriminant analysis to characterise marked differences in the behavioural phenotype of six inbred mouse strains. Behav Brain Res 105:207–217PubMedCrossRefGoogle Scholar
  29. Shirey JK, Xiang Z, Orton D, Brady AE, Johnson KA, Williams R, Ayala JE, Rodriguez AL, Wess J, Weaver D, Niswender CM, Conn PJ (2008) An allosteric potentiator of M4 mAChR modulates hippocampal synaptic transmission. Nat Chem Biol 4:42–50PubMedCrossRefGoogle Scholar
  30. SPSS Inc. (2004) SPSS base version 13.0 user manual. SPSS Inc., ChicagoGoogle Scholar
  31. Sugaya K, Clamp C, Bryan D, McKinney M (1997) mRNA for the m4 muscarinic receptor subtype is expressed in adult rat brain cholinergic neurons. Brain Res Mol Brain Res 50:305–313PubMedCrossRefGoogle Scholar
  32. Thomsen M, Caine SB (2005) Chronic intravenous drug self-administration in rats and mice. Curr Protoc Neurosci Chapter 9: Unit 9.20Google Scholar
  33. Thomsen M, Caine SB (2006) Cocaine self-administration under fixed and progressive ratio schedules of reinforcement: comparison of C57BL/6J, 129X1/SvJ, and 129 S6/SvEvTac inbred mice. Psychopharmacol (Berl) 184:145–154CrossRefGoogle Scholar
  34. Thomsen M, Woldbye DP, Wortwein G, Fink-Jensen A, Wess J, Caine SB (2005) Reduced cocaine self-administration in muscarinic M5 acetylcholine receptor-deficient mice. J Neurosci 25:8141–8149PubMedCrossRefGoogle Scholar
  35. Thomsen M, Hall FS, Uhl GR, Caine SB (2009a) Dramatically decreased cocaine self-administration in dopamine but not serotonin transporter knock-out mice. J Neurosci 29:1087–1092PubMedCrossRefGoogle Scholar
  36. Thomsen M, Han DD, Gu HH, Caine SB (2009b) Lack of cocaine self-administration in mice expressing a cocaine-insensitive dopamine transporter. J Pharmacol Exp Ther 331(1):204–211PubMedCrossRefGoogle Scholar
  37. Tzavara ET, Bymaster FP, Davis RJ, Wade MR, Perry KW, Wess J, McKinzie DL, Felder C, Nomikos GG (2004) M4 muscarinic receptors regulate the dynamics of cholinergic and dopaminergic neurotransmission: relevance to the pathophysiology and treatment of related CNS pathologies. FASEB J 18:1410–1412PubMedGoogle Scholar
  38. Vilaro MT, Mengod G, Palacios JM (1993) Advances and limitations of the molecular neuroanatomy of cholinergic receptors: the example of multiple muscarinic receptors. Prog Brain Res 98:95–101PubMedCrossRefGoogle Scholar
  39. Weiner DM, Levey AI, Brann MR (1990) Expression of muscarinic acetylcholine and dopamine receptor messenger-RNAs in rat basal ganglia. Proc Natl Acad Sci USA 87:7050–7054PubMedCrossRefGoogle Scholar
  40. Wess J (2004) Muscarinic acetylcholine receptor knockout mice: novel phenotypes and clinical implications. Annu Rev Pharmacol Toxicol 44:423–450PubMedCrossRefGoogle Scholar
  41. Wess J, Eglen RM, Gautam D (2007) Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development. Nat Rev Drug Discov 6:721–733PubMedCrossRefGoogle Scholar
  42. Wise RA (1996) Neurobiology of addiction. Curr Opin Neurobiol 6:243–251PubMedCrossRefGoogle Scholar
  43. Yasuda RP, Ciesla W, Flores LR, Wall SJ, Li M, Satkus SA, Weisstein JS, Spagnola BV, Wolfe BB (1993) Development of antisera selective for M4 and M5 muscarinic cholinergic receptors: distribution of m4 and m5 receptors in rat brain. Mol Pharmacol 43:149–157PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Lene S. Schmidt
    • 1
  • Morgane Thomsen
    • 3
  • Pia Weikop
    • 1
  • Ditte Dencker
    • 1
  • Jürgen Wess
    • 4
  • David P. D. Woldbye
    • 1
    • 2
  • Gitta Wortwein
    • 1
  • Anders Fink-Jensen
    • 1
    • 5
  1. 1.Laboratory of NeuropsychiatryRigshospitalet University HospitalCopenhagenDenmark
  2. 2.Department of Neuroscience and PharmacologyUniversity of CopenhagenCopenhagenDenmark
  3. 3.Alcohol and Drug Abuse Research CenterMcLean Hospital, Harvard Medical SchoolBelmontUSA
  4. 4.Molecular Signaling Section, Laboratory of Bioorganic ChemistryNIDDK, NIHBethesdaUSA
  5. 5.Laboratory of Neuropsychiatry and Psychiatric Centre CopenhagenUniversity of CopenhagenCopenhagenDenmark

Personalised recommendations